Graypoint LLC’s Outlook Therapeutics OTLK Stock Holding History

Graypoint LLC’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,875	Closed	-$46K	–	346
2022 Q3	$46K	Hold	1,875	–	–	0.01%	315
2022 Q2	$38K	Sell	1,875 -625	-25%	-$18K	﹤0.01%	293
2022 Q1	$89K	Buy	+2,500	New	+$78.1K	0.01%	314

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Graypoint LLC's OTLK Position: Q4 2022 in Review

Graypoint LLC sold out of Outlook Therapeutics (OTLK) in Q4 2022, closing a stake of 1,875 shares — an estimated $46K sold.

Graypoint LLC first reported a position in OTLK in Q1 2022 and held it in 3 quarters. The position peaked at $89K in Q1 2022. 75 funds tracked by Wall St. Rank hold OTLK as of Q4 2022.

Graypoint LLC reported no remaining Outlook Therapeutics position as of Q4 2022 after selling out during the quarter.
Graypoint LLC sold 1,875 Outlook Therapeutics shares in Q4 2022, an estimated $46K.
Graypoint LLC first reported a position in Outlook Therapeutics in Q1 2022 and held it in 3 quarters.
Graypoint LLC's Outlook Therapeutics position peaked at $89K in Q1 2022.
75 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2022.

Based on Graypoint LLC's 13F filing for Q4 2022, filed 31 Jan 2023.